Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Common Equity (2016 - 2025)

Palisade Bio has reported Common Equity over the past 16 years, most recently at $129.4 million for Q4 2025.

  • Quarterly Common Equity rose 1626.91% to $129.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $129.4 million through Dec 2025, up 1626.91% year-over-year, with the annual reading at $129.4 million for FY2025, 1626.91% up from the prior year.
  • Common Equity was $129.4 million for Q4 2025 at Palisade Bio, up from $3.2 million in the prior quarter.
  • Over five years, Common Equity peaked at $129.4 million in Q4 2025 and troughed at -$20.1 million in Q1 2021.
  • The 5-year median for Common Equity is $7.4 million (2021), against an average of $12.3 million.
  • Year-over-year, Common Equity tumbled 96.14% in 2021 and then surged 1626.91% in 2025.
  • A 5-year view of Common Equity shows it stood at $7.4 million in 2021, then skyrocketed by 69.44% to $12.5 million in 2022, then dropped by 9.34% to $11.3 million in 2023, then tumbled by 33.78% to $7.5 million in 2024, then surged by 1626.91% to $129.4 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Common Equity are $129.4 million (Q4 2025), $3.2 million (Q3 2025), and $2.6 million (Q2 2025).